J Vet Sci.  2020 Mar;21(2):e23. 10.4142/jvs.2020.21.e23.

Specific urinary metabolites in canine mammary gland tumors

Affiliations
  • 1Department of Chemistry, Biochemistry and Biophysics, University of Veterinary Medicine and Pharmacy in Košice, 041 81 Košice, Slovakia
  • 2Section of Surgery, Orthopaedics, Roentgenology and Reproduction, Small Animal Clinic, University Veterinary Hospital, University of Veterinary Medicine and Pharmacy in Košice, 041 81 Košice, Slovakia

Abstract

The identification of biomarkers that distinguish diseased from healthy individuals is of great interest in human and veterinary fields. In this research area, a metabolomic approach and its related statistical analyses can be useful for biomarker determination and allow noninvasive discrimination of healthy volunteers from breast cancer patients. In this study, we focused on the most common canine neoplasm, mammary gland tumor, and herein, we describe a simple method using ultra-high-performance liquid chromatography to determine the levels of tyrosine and its metabolites (epinephrine, 3,4-dihydroxy-L-phenylalanine, 3,4-dihydroxyphenylacetic acid, and vanillylmandelic acid), tryptophan and its metabolites (5-hydroxyindolacetic acid, indoxyl sulfate, serotonin, and kynurenic acid) in canine mammary cancer urine samples. Our results indicated significantly increased concentrations of three tryptophan metabolites, 5-hydroxyindolacetic acid (p < 0.001), serotonin, indoxyl sulfate (p < 0.01), and kynurenic acid ((p < 0.05), and 2 tyrosine metabolites, 3,4-dihydroxy-L-phenylalanine (p < 0.001), and epinephrine (p < 0.05) in urine samples from the mammary gland tumor group compared to concentrations in urine samples from the healthy group. The results indicate that select urinary tyrosine and tryptophan metabolites may be useful as non-invasive diagnostic markers as well as in developing a therapeutic strategy for canine mammary gland tumors.

Keyword

Canine mammary cancer; urine metabolites; UHPLC

Figure

  • Fig. 1. Urinary metabolite to creatinine ratios in mammary gland cancer and healthy control dogs. Horizontal lines represent median values. TYR, tyrosine; E, epinephrine; L-DOPA, 3,4-dihydroxy-L-phenylalanine; DOPAC, 3,4-dihydroxyphenylacetic acid; VMA, vanillylmandelic acid; TRP, tryptophan; 5-HIAA, 5-hydroxyindolacetic acid; IS, indoxyl sulfate; 5-HT, serotonin; KYNA, kynurenic acid.


Reference

References

1. Peña L, Gama A, Goldschmidt MH, Abadie J, Benazzi C, Castagnaro M, Díez L, Gärtner F, Hellmén E, Kiupel M, Millán Y, Miller MA, Nguyen F, Poli A, Sarli G, Zappulli V, de las Mulas JM. Canine mammary tumors: a review and consensus of standard guidelines on epithelial and myoepithelial phenotype markers, HER2, and hormone receptor assessment using immunohistochemistry. Vet Pathol. 2014; 51:127–145.
2. Sorenmo K. Canine mammary gland tumors. Vet Clin North Am Small Anim Pract. 2003; 33:573–596.
Article
3. Concannon PW, Spraker TR, Casey HW, Hansel W. Gross and histopathologic effects of medroxyprogesterone acetate and progesterone on the mammary glands of adult beagle bitches. Fertil Steril. 1981; 36:373–387.
4. Sorenmo KU, Kristiansen VM, Cofone MA, Shofer FS, Breen AM, Langeland M, Mongil CM, Grondahl AM, Teige J, Goldschmidt MH. Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence. Vet Comp Oncol. 2009; 7:162–172.
Article
5. Moe L. Population-based incidence of mammary tumours in some dog breeds. J Reprod Fertil Suppl. 2001; 57:439–443.
6. Nguyen F, Peña L, Ibisch C, Loussouarn D, Gama A, Rieder N, Belousov A, Campone M, Abadie J. Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors. Breast Cancer Res Treat. 2018; 167:635–648.
Article
7. Johnson CH, Manna SK, Krausz KW, Bonzo JA, Divelbiss RD, Hollingshead MG, Gonzalez FJ. Global metabolomics reveals urinary biomarkers of breast cancer in a mcf-7 xenograft mouse model. Metabolites. 2013; 3:658–672.
Article
8. Wu G. Amino acids: metabolism, functions, and nutrition. Amino Acids. 2009; 37:1–17.
Article
9. Wiggins T, Kumar S, Markar SR, Antonowicz S, Hanna GB. Tyrosine, phenylalanine, and tryptophan in gastroesophageal malignancy: a systematic review. Cancer Epidemiol Biomarkers Prev. 2015; 24:32–38.
Article
10. Oto J, Suzue A, Inui D, Fukuta Y, Hosotsubo K, Torii M, Nagahiro S, Nishimura M. Plasma proinflammatory and anti-inflammatory cytokine and catecholamine concentrations as predictors of neurological outcome in acute stroke patients. J Anesth. 2008; 22:207–212.
Article
11. Heng B, Lim CK, Lovejoy DB, Bessede A, Gluch L, Guillemin GJ. Understanding the role of the kynurenine pathway in human breast cancer immunobiology. Oncotarget. 2016; 7:6506–6520.
Article
12. Kuo TR, Chen JS, Chiu YC, Tsai CY, Hu CC, Chen CC. Quantitative analysis of multiple urinary biomarkers of carcinoid tumors through gold-nanoparticle-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Chim Acta. 2011; 699:81–86.
Article
13. Chung KT, Gadupudi GS. Possible roles of excess tryptophan metabolites in cancer. Environ Mol Mutagen. 2011; 52:81–104.
Article
14. Mulder EJ, Anderson GM, Kemperman RF, Oosterloo-Duinkerken A, Minderaa RB, Kema IP. Urinary excretion of 5-hydroxyindoleacetic acid, serotonin and 6-sulphatoxymelatonin in normoserotonemic and hyperserotonemic autistic individuals. Neuropsychobiology. 2010; 61:27–32.
Article
15. Porto-Figueira P, Pereira JA, Câmara JS. Exploring the potential of needle trap microextraction combined with chromatographic and statistical data to discriminate different types of cancer based on urinary volatomic biosignature. Anal Chim Acta. 2018; 1023:53–63.
Article
16. Chen Y, Zhang R, Song Y, He J, Sun J, Bai J, An Z, Dong L, Zhan Q, Abliz Z. RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer. Analyst (Lond). 2009; 134:2003–2011.
Article
17. Cascino A, Cangiano C, Ceci F, Franchi F, Mineo T, Mulieri M, Muscaritoli M, Rossi Fanelli F. Increased plasma free tryptophan levels in human cancer: a tumor related effect? Anticancer Res. 1991; 11:1313–1316.
18. Valko-Rokytovská M, Očenáš P, Salayová A, Kostecká Z. New developed UHPLC method for selected urine metabolites. J Chromatogr Sep Tech. 2018; 9:1000404.
Article
19. Nam H, Chung BC, Kim Y, Lee K, Lee D. Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification. Bioinformatics. 2009; 25:3151–3157.
Article
20. Mishra P, Ambs S. Metabolic signatures of human breast cancer. Mol Cell Oncol. 2015; 2:e992217.
Article
21. Prendergast GC. Cancer: why tumours eat tryptophan. Nature. 2011; 478:192–194.
22. Jose J, Tavares CD, Ebelt ND, Lodi A, Edupuganti R, Xie X, Devkota AK, Kaoud TS, Van Den Berg CL, Anslyn EV, Tiziani S, Bartholomeusz C, Dalby KN. Serotonin analogues as inhibitors of breast cancer cell growth. ACS Med Chem Lett. 2017; 8:1072–1076.
Article
23. Miller AG, Brown H, Degg T, Allen K, Keevil BG. Measurement of plasma 5-hydroxyindole acetic acid by liquid chromatography tandem mass spectrometry–comparison with HPLC methodology. J Chromatogr B Analyt Technol Biomed Life Sci. 2010; 878:695–699.
Article
24. Yamaguchi J, Tanaka T, Inagi R. Effect of AST-120 in chronic kidney disease treatment: still a controversy? Nephron. 2017; 135:201–206.
Article
25. Sagan D, Kocki T, Patel S, Kocki J. Utility of kynurenic acid for non-invasive detection of metastatic spread to lymph nodes in non-small cell lung cancer. Int J Med Sci. 2015; 12:146–153.
Article
26. Xie Z, Lorkiewicz P, Riggs DW, Bhatnagar A, Srivastava S. Comprehensive, robust, and sensitive UPLC-MS/MS analysis of free biogenic monoamines and their metabolites in urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2018; 1099:83–91.
Article
27. Muthuswamy R, Okada NJ, Jenkins FJ, McGuire K, McAuliffe PF, Zeh HJ, Bartlett DL, Wallace C, Watkins S, Henning JD, Bovbjerg DH, Kalinski P. Epinephrine promotes COX-2-dependent immune suppression in myeloid cells and cancer tissues. Brain Behav Immun. 2017; 62:78–86.
Article
28. Barollo S, Bertazza L, Watutantrige-Fernando S, Censi S, Cavedon E, Galuppini F, Pennelli G, Fassina A, Citton M, Rubin B, Pezzani R, Benna C, Opocher G, Iacobone M, Mian C. Overexpression of L-Type amino acid transporter 1 (LAT1) and 2 (LAT2): Novel markers of neuroendocrine tumors. PLoS One. 2016; 11:e0156044.
Article
29. Zhang A, Sun H, Wang P, Han Y, Wang X. Recent and potential developments of biofluid analyses in metabolomics. J Proteomics. 2012; 75:1079–1088.
Article
30. McCartney A, Vignoli A, Biganzoli L, Love R, Tenori L, Luchinat C, Di Leo A. Metabolomics in breast cancer: a decade in review. Cancer Treat Rev. 2018; 67:88–96.
Article
Full Text Links
  • JVS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr